Concord Biotech Limited (CONCORDBIO) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Concord Biotech Limited stock ₹388, price ₹597, that is 35.0% below the price, quality 57 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
39‑month range ₹463.03 – ₹1,695 · fair‑value band ₹216.94 – ₹615.66 · the ₹596.80 price screens above the ₹387.76 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 6, 2026.
Follow Concord Biotech in your weekly email
Every Wednesday you see whether Concord Biotech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally.
Show moreShow less
The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas.
It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment.
In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications.
Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products.
Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Stock analysis
Concord Biotech Limited (CONCORDBIO) currently trades at ₹596.80, while our model-based Fair Value estimate is ₹387.76, 35% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹245.93 per share, and 0 of the 26 models we run sit above the ₹596.80 price.
Bear case: the Asset-Based group reads lowest at ₹49.34, and 26 of the 26 models stay below the price. Data coverage for this calculation is high.
Scenario range: ₹216.94 (bear) to ₹615.66 (bull), the price of ₹596.80 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Concord Biotech Limited reported revenue of ₹10.5B in FY2026 versus ₹7.1B in FY2022, a compound +10.3%/yr. Reported net income was ₹2.6B in FY2026, compounding +10.5%/yr from FY2022.
Key figures
Market cap ₹141B (≈ $1.5B) Small · P/E ratio 44.7 · P/S ratio 12.1 · EPS (TTM) ₹13.36 · Dividend yield 0.6% · Net margin 24.1% · Return on equity 14.3% · Return on assets (EBIT) 27.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 77 out of 100 (low confidence).
What moves the price
The share trades about 25% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −35%, CONCORDBIO screens richer than that median.
Fair Value models
Bear₹216.94Fair Value ₹387.76Bull₹615.66
Price ₹596.80 · Downside -35.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹5.91 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.88/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−12.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.3%
Start year 2021 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.8%
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+8.9%
Earnings growth per share plus dividend.
Earnings per share, growth per year+8.3%
Dividend (yield on the price)0.6%
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+26.1%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+19.0%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +21.1% a year for the price and +14.3% for the forecasts.
Compare Concord Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Beats the industry median on 6/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score57 · Top 25%
Fair Value upside−35.0% · Below median
Profitability
Return on equity (12 months)14.3% · Top 25%
Return on assets11.7% · Top 25%
Net margin (12 months)24.1% · Top 25%
Operating margin (12 months)27.8% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)25.1% · Top 25%
Dividend yield (12 months)0.6% · Below median
Valuation Multiplesvs Biotechnology median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Concord Biotech Limited (CONCORDBIO) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of ₹387.76 versus a price of ₹596.80, about 35% lower (overvalued).
What is the fair value of CONCORDBIO?
Our model-based fair value for Concord Biotech Limited is ₹387.76 (as of Nov 6, 2026), built from audited fundamentals. The current price: ₹596.80.
What is the quality score of CONCORDBIO?
Concord Biotech Limited has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Concord Biotech Limited (CONCORDBIO)?
Our model-based price target is the fair value of ₹387.76 (as of Nov 6, 2026) from 26 valuation models. Cautious scenario ₹216.94, optimistic scenario ₹615.66. It is a calculation from audited fundamentals, not an analyst target.
What is the Concord Biotech Limited stock forecast for 2026?
Our models put fair value at ₹387.76, about 35% lower versus a price of ₹596.80 (overvalued). Cautious scenario ₹216.94, optimistic scenario ₹615.66. The calculation is refreshed regularly with new filings.
What is the revenue of Concord Biotech Limited (CONCORDBIO)?
Concord Biotech Limited reported trailing-twelve-month revenue of about ₹11.7B (latest available figure, as of Nov 6, 2026).
Does Concord Biotech Limited pay a dividend?
Concord Biotech Limited currently shows a dividend yield of 0.63% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Concord Biotech Limited (CONCORDBIO) and when is the ex-dividend date?
Concord Biotech Limited pays a dividend of ₹3.78 per share a year, a dividend yield of 0.6%. The last ex-dividend date was Jul 24, 2026. The payout ratio is 28.3% of earnings. Free cash flow covers the dividend 2.20 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Concord Biotech Limited (CONCORDBIO)?
For today's price to be fair in a discounted-cash-flow model, Concord Biotech Limited would have to grow free cash flow by +26.1 % per year for five years (discount rate 12.4 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.3 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of CONCORDBIO use?
Our models discount Concord Biotech Limited at 12.4 %: a base by market capitalisation (small), damped by beta 0.44, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Concord Biotech Limited that is +26.1 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (12.4 %) and the same formula as our fair value.
How much growth has Concord Biotech Limited (CONCORDBIO) delivered so far?
Over the past 5 years revenue at Concord Biotech Limited grew +11.3 % a year. The price currently implies free-cash-flow growth of +26.1 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Concord Biotech Limited (CONCORDBIO) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Concord Biotech Limited (+26.1 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Concord Biotech Limited (CONCORDBIO)?
The free-cash-flow yield on the price is 2.79 %: that much free cash flow Concord Biotech Limited produces per unit of market value. When it exceeds the discount rate of our models (12.4 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Concord Biotech Limited (CONCORDBIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Concord Biotech Limited it is ₹387.76 per share (as of Nov 6, 2026), against a price of ₹596.80. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Concord Biotech Limited stock overvalued or undervalued in 2026?
As of Nov 6, 2026, CONCORDBIO trades above its calculated fair value: price ₹596.80, fair value ₹387.76, a gap of about −35% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CONCORDBIO?
No. The price is what the market pays today (₹596.80); the fair value is what the company's own numbers justify (₹387.76). For Concord Biotech Limited the two are ₹209.04 per share apart. That gap is exactly why we show both numbers side by side.
How much is Concord Biotech Limited worth?
The market values Concord Biotech Limited at about ₹141B (market capitalisation, as of Nov 6, 2026). Per share that is ₹596.80; our models calculate a fair value of ₹387.76 per share.
What do the bullish and bearish scenarios say about CONCORDBIO?
Our models span a range for Concord Biotech Limited: cautious scenario ₹216.94, base ₹387.76, optimistic ₹615.66 per share (as of Nov 6, 2026, price ₹596.80). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of CONCORDBIO?
Concord Biotech Limited trades at a price-to-earnings ratio of 44.7 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹387.76 is built from several models across several years. Other multiples: P/B 7.0, P/S 12.1, EV/EBITDA 34.1.
How solid is the balance sheet of Concord Biotech Limited (CONCORDBIO)?
Balance-sheet figures for Concord Biotech Limited (as of Nov 6, 2026): return on equity 14.3%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is CONCORDBIO from its 52-week high?
Concord Biotech Limited trades at ₹596.80, about 25% below its 52-week high of ₹793.75 and 18% above the low of ₹504.38 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹387.76 is for.
Which stocks are comparable to Concord Biotech Limited?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Concord Biotech Limited stock attractive at the current price?
The data as of Nov 6, 2026: price ₹596.80, calculated fair value ₹387.76 (−35%), Quality Score 57/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CONCORDBIO calculated?
We run Concord Biotech Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹387.76 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Concord Biotech Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Concord Biotech Limited (CONCORDBIO)?
The closing price on Nov 9, 2026 was ₹596.80. Our model-based fair value is ₹387.76, about 35% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Concord Biotech Limited right now?
The model range is unusually wide (₹216.94 to ₹615.66). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Concord Biotech Limited
How large is the market capitalisation of Concord Biotech Limited (CONCORDBIO)?
The market capitalisation of Concord Biotech Limited is ₹141B (≈ $1.5B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Concord Biotech Limited (CONCORDBIO)?
The price-to-sales ratio of Concord Biotech Limited is 12.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Concord Biotech Limited (CONCORDBIO)?
Earnings per share at Concord Biotech Limited are ₹13.36 (price ÷ EPS = P/E 44.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Concord Biotech Limited (CONCORDBIO)?
The dividend yield of Concord Biotech Limited is 0.6% (payout 28.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Concord Biotech Limited (CONCORDBIO)?
The net margin of Concord Biotech Limited is 24.1% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Concord Biotech Limited (CONCORDBIO)?
The return on equity (ROE) of Concord Biotech Limited is 14.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Concord Biotech Limited (CONCORDBIO)?
On an EBIT basis the return on assets of Concord Biotech Limited is 27.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Concord Biotech Limited (CONCORDBIO)?
The operating margin of Concord Biotech Limited is 27.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Concord Biotech Limited (CONCORDBIO)?
Revenue at Concord Biotech Limited is growing +25.1% versus a year earlier (3y avg +7.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Concord Biotech Limited (CONCORDBIO)?
Earnings per share at Concord Biotech Limited are growing +10.3% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Concord Biotech Limited (CONCORDBIO) hold?
Concord Biotech Limited holds more cash than debt, ₹113M net (fiscal year 2026). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Concord Biotech Limited in the live analysis
One click puts Concord Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Broad data
Nov 6, 2026